1976
Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited.
Bunn P, Schein P, Banks P, DeVita V. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood 1976, 47: 3-10. PMID: 1106798, DOI: 10.1182/blood.v47.1.3.bloodjournal4713.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBrainCentral Nervous System DiseasesCerebrospinal FluidFemaleHumansLymphomaLymphoma, Large B-Cell, DiffuseMaleMeningesMiddle AgedConceptsLeptomeningeal lymphomaCentral nervous systemHistologic types of non-Hodgkin's lymphomasProgression of systemic diseaseCentral nervous system complicationsCentral nervous system therapyProphylactic CNS therapySite of relapseBone marrow involvementNon-Hodgkin's lymphomaIntrathecal drug administrationPatient's clinical courseCerebrospinal fluid cytologyResponse to therapyNervous system complicationsNervous system therapyBone marrow cavityUndifferentiated lymphomaMarrow involvementClinical remissionSystemic therapyCNS therapyClinical courseHistological typeSystemic complications
1970
The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs.
Vogel C, Denham C, Waalkes T, DeVita V. The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs. Cancer Research 1970, 30: 1651-7. PMID: 5457935.Peer-Reviewed Original ResearchConceptsPhysiological disposition
1966
Candida Meningitis
DeVITA V, UTZ J, WILLIAMS T, CARBONE P. Candida Meningitis. JAMA Internal Medicine 1966, 117: 527-535. PMID: 5906646, DOI: 10.1001/archinte.1966.03870100055011.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmphotericin BAnti-Bacterial AgentsCandidiasisCerebrospinal FluidFemaleHumansMeningitisConceptsCandida meningitisChronic myelogenous leukemiaBlastic crisisMyelogenous leukemiaBlastic crisis of chronic myelogenous leukemiaCrisis of chronic myelogenous leukemiaTreated with amphotericin BAmphotericin BLaboratory featuresLaboratory findingsTreated patientsTherapeutic resultsPatientsMeningitisWhite housewifePresent reportLeukemiaWorld literatureCandidaTerminal diseaseRemissionReportsClinicDisease
1964
SOME PHARMACOLOGIC PROPERTIES OF A NEW ANTITUMOR AGENT, N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HYDROCHLORIDE (NSC-77213).
OLIVERIO V, DENHAM C, DEVITA V, KELLY M. SOME PHARMACOLOGIC PROPERTIES OF A NEW ANTITUMOR AGENT, N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HYDROCHLORIDE (NSC-77213). Cancer Chemotherapy Reports 1964, 42: 1-7. PMID: 14226125.Peer-Reviewed Original Research